.webp)
.jpeg)
Starting January 2026, the NHS will introduce the MMRV vaccine, combining measles, mumps, rubella, and chickenpox in two doses at ages 12 and 18 months—affecting over 500,000 children annually. The change aims to reduce school absences, parental work disruption, and save millions in healthcare costs.
.jpeg)
Chickenpox, though often considered mild, can cause serious complications in adults, immunocompromised individuals, and pregnant women. Expanding coverage to all young children will curb virus circulation and protect vulnerable populations. The move mirrors successful programs in the US, Canada, and Australia, where uptake led to sharp declines in hospital admissions and complications
“Not only has VPAS … delivered value for money for the taxpayer … it has also saved people’s lives by supporting cancer patients and others with life-threatening conditions.” — Health Minister Will Quince, commenting on broader vaccination funding frameworks
The MMRV rollout marks a major advancement in preventive childhood healthcare—bringing lasting benefits to families and communities. At The Vesey, we support this proactive approach with: